# A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

> **NCT05742750** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 48 (estimated)

## Conditions studied

- Locally Advanced Biliary Tract Cancer
- Metastatic Biliary Tract Cancer

## Interventions

- **DRUG:** Camrelizumab and Apatinib Plus GP

## Key facts

- **NCT ID:** NCT05742750
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05742750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05742750, "A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05742750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*